Wedbush Securities Inc Exact Sciences Corp Transaction History

Wedbush Securities Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$65.94 - $99.04 $67,654 - $101,615	-1,026 Reduced 21.62%	3,719 $254,000
Q2 2023 Aug 14, 2023	SELL	$62.68 - $95.05 $38,360 - $58,170	-612 Reduced 11.42%	4,745 $446,000
Q1 2023 May 09, 2023	BUY	$47.19 - $70.77 $252,796 - $379,114	5,357 New	5,357 $363,000
Q2 2022 Jul 21, 2022	SELL	$35.61 - $76.23 $193,255 - $413,700	-5,427 Closed	0 $0
Q1 2022 Apr 19, 2022	SELL	$57.56 - $82.54 $62,970 - $90,298	-1,094 Reduced 16.78%	5,427 $379,000
Q4 2021 Jan 13, 2022	BUY	$72.5 - $100.68 $114,767 - $159,376	1,583 Added 32.06%	6,521 $507,000
Q3 2021 Oct 08, 2021	BUY	$90.24 - $124.05 $61,814 - $84,974	685 Added 16.11%	4,938 $471,000
Q2 2021 Jul 27, 2021	BUY	$93.66 - $139.27 $174,207 - $259,042	1,860 Added 77.73%	4,253 $528,000
Q1 2021 Apr 26, 2021	BUY	$116.57 - $155.01 $278,952 - $370,938	2,393 New	2,393 $315,000
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $197,725 - $282,108	-1,985 Closed	0 $0
Q3 2020 Oct 20, 2020	BUY	$72.92 - $102.01 $144,746 - $202,489	1,985 New	1,985 $202,000

667

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $9.91B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.